|
|
|
Volumn 56, Issue 2, 2001, Pages 131-133
|
|
Cost-effectiveness analysis of GEOLAM Sa3, a randomized placebo-controlled protocol of GM-CSF for elderly patients;Intérêt thérapeutique et économique du GM-CSF dans le traitement des leucémies aiguës myéloblastiques du sujet âgé: Protocole GOELAM Sa3
a
|
|
Author keywords
Acute myeloid leukaemia; Cost effectiveness; Elderly patients; GM CSF
|
|
Indexed keywords
RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
ACUTE GRANULOCYTIC LEUKEMIA;
ADULT;
AGED;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONFERENCE PAPER;
COST EFFECTIVENESS ANALYSIS;
DRUG EFFICACY;
FEMALE;
FRANCE;
GERIATRIC PATIENT;
HEALTH CARE COST;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
PRIORITY JOURNAL;
AGED;
COST-BENEFIT ANALYSIS;
DISEASE-FREE SURVIVAL;
FRANCE;
GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT;
HUMANS;
LEUKEMIA, MYELOCYTIC, ACUTE;
MIDDLE AGED;
PLACEBOS;
RETROSPECTIVE STUDIES;
SURVIVAL RATE;
|
|
EID: 0034968186
PISSN: 00405957
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (5)
|
|
References (6)
|
